Ovarian cancer (OC) is the second most common tumour and the most lethal gynaecological malignancy in females. Epithelial ovarian cancer (EOC) accounts for approximately 90% of OC ([@bib12]; [@bib23]). The initiation and development of EOC are characterised by the disruption of oncogenes and tumour-suppressor genes ([@bib30]). Recently, microRNAs (miRNAs) have been reported to be involved in OC pathogenesis ([@bib15]).

miRNAs are a class of short, endogenous single-stranded RNAs that regulate gene expression by base-pairing with target mRNAs, leading to translational repression or mRNA cleavage ([@bib13]). However, emerging evidence has revealed that miRNAs can enhance target gene expression at the posttranscriptional level ([@bib40]). For example, miR-490-3p upregulates endoplasmic reticulum--Golgi intermediate compartment 3 in human hepatocellular carcinoma cells ([@bib41]), miR-17-5p upregulates YES proto-oncogene 1 to modulate cell cycle progression and apoptosis in OC ([@bib29]), and miR-346 promotes the expression of human telomerase reverse transcriptase subunit in a G-rich RNA sequence binding factor 1-dependent manner ([@bib38]). miR-23a may function as an oncogene in laryngeal carcinoma ([@bib42]), colorectal cancer ([@bib31]), gastric cancer ([@bib33]), metastatic neuroblastoma tissues ([@bib9]), acute lymphoblastic leukemia ([@bib34]), bladder cancer ([@bib18]), glioblastoma ([@bib11]), and hepatocellular carcinoma ([@bib21]). Although miR-23a was reported to be upregulated in OC ([@bib35]), its function and underlying mechanism are not well studied in EOC.

NF-kappa-B (NF-*κ*B) is a transcription factor that has a critical role in innate immunity and other processes, such as cell survival, proliferation, and differentiation ([@bib20]). IKK-alpha (IKK*α*) is necessary for activation of the NF-*κ*B pathway, and activated NF-*κ*B translocates to the nucleus to modulate target gene expression ([@bib22]). Although NF-*κ*B activation associated with IKK*α* has been shown to be important in OC ([@bib32]), the underlying mechanism of miRNA regulation of IKK*α* remains unknown.

Suppression of tumorigenicity 7 like (ST7L) was identified based on its similarity to the ST7 tumour-suppressor gene ([@bib26]). The wingless-type MMTV integration site family (WNT) pathway is crucial for the regulation of cell proliferation, migration, and apoptosis. Abnormal expression of WNT signaling pathway components can trigger tumour development ([@bib3]; [@bib37]). Wnt2 is an important member of the wnt family. ST7L is a suppressor of wnt2 activation; it forms the wnt2-ST7-capping protein muscle Z-line, alpha 2 (CAPZA2) complex to inhibit WNT pathway activation ([@bib27]). An increasing number of studies have reported that wnt2 is frequently upregulated in various types of tumours, such as oesophageal cancer ([@bib16]) and colorectal cancer ([@bib25]). ST7L is downregulated in different cancers, including gastric cancer ([@bib28]) and glioma ([@bib7]). However, the significance of ST7L in EOC and the underlying mechanism have not been elucidated.

In this study, we demonstrated that miR-23a may function as an oncogene by directly upregulating IKK*α* to promote NF-*κ*B activation and by downregulating ST7L to activate the WNT/MAPK pathway in EOC cells. Collectively, these findings may provide insight into tumorigenesis and a potential biomarker for EOC.

Materials and Methods
=====================

Cell lines and transfection
---------------------------

OVCAR3 and SKOV3 cells were maintained in RPMI 1640 (Invitrogen, Carlsbad, CA, USA) supplemented with 10% FBS, 100 U ml^−1^ penicillin, and 100 μg ml^−1^ streptomycin in a humidified 5% (v/v) CO~2~ atmosphere at 37 °C. Transfections were performed using Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer\'s protocol.

Plasmid construction
--------------------

For miR-23a expression vector (pri-miR-23a), 307 bp containing miR-23a encoded region was amplified from genomic DNA and cloned into the pcDNA3 vector at BamHI and EcoRI sites. The 2′-*O*-methyl-modified miR-23a antisense oligonucleotide (ASO-miR-23a) was commercially synthesised as an inhibitor of miR-23a. The 3′UTRs of IKK*α* and ST7L that contain the miR-23a-binding sites and mutant 3′UTR fragments with mutant miR-23a-binding sites were obtained by annealing double-strand DNA and inserting it into the pcDNA3/EGFP vector. The pSilencer/shR-IKK*α* (shR-IKK*α*) and pSilencer/shR-ST7L (shR-ST7L) plasmids expressing siRNA targeting IKK*α* or ST7L were constructed by annealing double-strand hairpin cDNA and inserting it into the pSilencer 2.1-U6 neo vector (Ambion, Austin, TX, USA) at BamHI and EcoRI sites. The relevant control vector is pSilencer 2.1-U6 neo, which was named 'pSilencer\' in short in paper. The full-length sequences of human ST7L cDNA (NM_017744.4) were obtained by RT--PCR and cloned into pcDNA3 at KpnI and EcoRI sites. The resulting plasmid was termed pcDNA3/ST7L. All primers for PCR amplification are provided in [Supplementary Table S1](#sup1){ref-type="supplementary-material"}.

Cell proliferation assay
------------------------

OVCAR3 and SKOV3 cells were seeded in 96-well plates at 4000 cells per well 1 day prior to transfection. The cells were transfected with pri-miR-23a, ASO-miR-23a or the respective control. Cell viability at 48 and 72 h posttransfection was determined by MTT assay. The absorbance at 570 nm was measured using a Quant Universal Microplate Spectrophotometer (BioTek, Winooski, VT, USA).

Colony-formation assay
----------------------

For the colony-formation assays, the cells were counted at 24 h posttransfection and seeded into 12-well plates in triplicate at a density of 400 cells per well (OVCAR3 cells) or 300 cells per well (SKOV3 cells). Culture medium was replaced every 3 days. The cells were stained with crystal violet, and colonies containing \>50 cells were counted.

Prediction of miRNA targets
---------------------------

The hypothetical targets of miR-23a were predicted using Targetscan 7.0, PicTar, and miRanda.

EGFP reporter assay
-------------------

Cells were seeded in 48-well plates 1 day before transfection and then cotransfected with pri-miR-23a or ASO-miR-23a and pcDNA3/EGFP-IKK*α* 3′UTR, pcDNA3/EGFP-ST7L 3′UTR, pcDNA3/EGFP-IKK*α* 3′UTR mut, or pcDNA3/EGFP-ST7L 3′UTR mut. The vector pDsRed2-N1 (Clontech, Mountain View, CA, USA), which expresses RFP, was included for transfection normalization. After transfection for 48 h, the cells were lysed using radio-immunoprecipitation assay (RIPA) lysis buffer, and the EGFP and RFP intensities were measured with a fluorescence spectrophotometer (F4500, Hitachi, Tokyo, Japan).

RT--qPCR
--------

First-strand cDNA was generated through reverse transcription of total cellular RNA using M-MLV reverse transcriptase (Promega, Madison, WI, USA). The SYBR Premix Ex Taq Kit (TaKaRa, Shiga, Japan) was used according to the manufacturer\'s instructions, and RT--qPCR was performed and analyzed using the iQ5 Detection System (Bio-Rad, Hercules, CA, USA). All the primers ([Supplementary Table S1](#sup1){ref-type="supplementary-material"}) were purchased from AuGCT, Inc. (Beijing, China).

Western blotting analysis
-------------------------

Cell extracts were prepared with RIPA lysis buffer and analyzed by immunoblotting. Antibodies of ICAM-1, Vimentin, E-cadherin, wnt2, Dvl1, MAP3K7, *β*-catenin, GAPDH, CENPA, ST7L, and IKK*α* were purchased from Tianjin Saier Biotech (Tianjin, China) and the secondary goat anti-rabbit antibody was obtained from Sigma-Aldrich (St Louis, MO, USA). LabWorks Image Acquisition and Analysis Software (UVP, Upland, CA, USA) were used to quantify band intensities.

Immunofluorescent staining
--------------------------

Cells transfected with the indicated plasmids were seeded in 14-well plates and then treated with 20 ng *μ*l^−1^ TNF-*α* for 4 h before immunofluorescent staining. The subsequent protocol was previously reported by [@bib8]).

Wound-healing assay
-------------------

Cells were cultured in 12-well plates. When cell confluence reached approximately 80%, scratches were generated using a 50-μl pipette tip. Non-adherent cells were removed by PBS washes. Wounded cultures were incubated in medium containing 5% FBS for 0, 48, and 72 h. Five fields of observation were randomly captured for each well.

Transwell assays
----------------

These assays were performed as described by [@bib19]).

Cell cycle and apoptosis flow cytometry analyses
------------------------------------------------

These analyses were conducted according to the protocol provided by KeyGen Biotech (<http://www.keygentec.com.cn>).

TOP/FOP flash reporter assays
-----------------------------

To assay the transcriptional activity of Wnt pathway ([@bib24]), cells were transiently transfected with a mixture of corresponding plasmids, pTOP/Flash, or pFOP/Flash and pRL-TK vectors as previously controls. Dual Luciferase Reporter Assay System was used to assay Firefly and Renilla Luciferase activity ratio.

Statistical analysis
--------------------

Student\'s *t*-test was used to compare differences between two groups. *P*\<0.05 was considered statistically significant. \**P*\<0.05; \*\**P*\<0.01; \*\*\**P*\<0.001.

Results
=======

miR-23a is upregulated and promotes tumorigenic activity in EOC cells
---------------------------------------------------------------------

miR-23a was reported to be upregulated in OC tissue ([@bib35]). To determine the role of miR-23a in EOC cells, gain- and loss-of-function assays were performed in OVCAR3 and SKOV3 cells transfected with either pri-miR-23a or ASO-miR-23a. RT--qPCR showed that pri-miR-23a resulted in a 6--7-fold increase of miR-23a levels and that ASO-miR-23a reduced miR-23a levels by 60--70% relative to controls ([Figure 1A](#fig1){ref-type="fig"}). MTT assays showed that miR-23a promoted the viability of OVCAR3 and SKOV3 cells ([Figure 1B](#fig1){ref-type="fig"}). The colony-formation rates of OVCAR3 and SKOV3 cells were increased by pri-miR-23a and decreased by ASO-miR-23a ([Figure 1C](#fig1){ref-type="fig"}) and colony-formation rates of untreated OVCAR3 and SKOV3 cells as control group are shown in [Supplementary Figure S1A](#sup1){ref-type="supplementary-material"}. Cell cycle analysis showed that miR-23a overexpression caused an increase in OVCAR3 ([Figure 1D](#fig1){ref-type="fig"}) and SKOV3 ([Supplementary Figure S1B](#sup1){ref-type="supplementary-material"}) cells in S phase and a decrease in those in G1 phase. Furthermore, apoptosis analysis showed a lower apoptosis rate among OVCAR3 ([Figure 1E](#fig1){ref-type="fig"}) and SKOV3 ([Supplementary Figure S1C](#sup1){ref-type="supplementary-material"}) cells when miR-23a was overexpressed. Wound-healing assays revealed that EOC cells\' migration were significantly promoted by miR-23a but inhibited by ASO-miR-23a ([Figure 1F](#fig1){ref-type="fig"}). Consistently, transwell assay results showed that cells\' invasion were increased by pri-miR-23a and inhibited by ASO-miR-23a ([Figure 1G](#fig1){ref-type="fig"}). Taken together, these results indicate that miR-23a may have an oncogenic role in EOC cells.

miR-23a upregulates IKK*α* expression but downregulates ST7L expression by binding their 3′UTRs in EOC cells
------------------------------------------------------------------------------------------------------------

Target prediction using bioinformatics methods suggested hundreds of candidate targets for miR-23a; we chose IKK*α* and ST7L as putative targets for further study after considering available functional knowledge. To validate whether IKK*α* and ST7L are directly targeted by miR-23a, we performed an EGFP reporter assay using EGFP reporter vectors containing either the wild-type 3′UTR or a mutant 3′UTR with a mutation in the complementary seed sequence of IKK*α* and ST7L ([Figure 2A](#fig2){ref-type="fig"}). In OVCAR3 and SKOV3 cells, pri-miR-23a significantly enhanced the fluorescence intensity of pcDNA3/EGFP-IKK*α* 3′UTR ([Figure 2B](#fig2){ref-type="fig"}), whereas overexpression of miR-23a significantly decreased the intensity of pcDNA3/EGFP-ST7L 3′UTR ([Figure 2D](#fig2){ref-type="fig"}). However, EGFP intensity with the mutant 3′UTR of IKK*α* or ST7L was not influenced by either overexpression or inhibition of miR-23a ([Figure 2C and E](#fig2){ref-type="fig"}). These results suggest that miR-23a may directly target IKK*α* and ST7L but has opposite effects.

Next we further determined the effect of miR-23a on endogenous IKK*α* and ST7L expression. RT--qPCR showed that IKK*α* mRNA levels were increased but that ST7L mRNA levels were decreased in OVCAR3 and SKOV3 cells transfected with pri-miR-23a ([Figure 2F](#fig2){ref-type="fig"}). Furthermore, western blotting assays showed a similar relationship: miR-23a increased IKK*α* expression but decreased ST7L expression ([Figure 2G](#fig2){ref-type="fig"}, [Supplementary Figure S2](#sup1){ref-type="supplementary-material"}). These results indicate that miR-23a promotes IKK*α* expression but suppresses ST7L expression at both the mRNA and protein levels in EOC cells.

IKK*α* promotes EOC cell growth, migration, and invasion
--------------------------------------------------------

An abundance of data indicates that IKK*α* functions as an oncogene and has an important role in activating the NF-*κ*B pathway ([@bib4]; [@bib1]). To determine the effect of IKK*α* on cell proliferation, migration, and invasion in EOC, we depleted its expression by a specific shRNA. RT--qPCR and western blotting assays validated the efficiency of shR-IKK*α* ([Figure 3A and B](#fig3){ref-type="fig"}). Next MTT and colony-formation assays were used to examine the influence of shR-IKK*α* on OVCAR3 and SKOV3 cells\' proliferation. Knockdown of IKK*α* reduced cell viability ([Figure 3C](#fig3){ref-type="fig"}) and relative colony-formation rate ([Figure 3D](#fig3){ref-type="fig"}). Cellular apoptosis assays showed that shR-IKK*α* increased the apoptosis of OVCAR3 and SKOV3 cells ([Figure 3E](#fig3){ref-type="fig"}), but no difference of cell cycle analysis was shown in [Supplementary Figure S3A](#sup1){ref-type="supplementary-material"}.

Wound-healing assays showed that IKK*α* knockdown significantly impeded OVCAR3 and SKOV3 cells\' migration ([Figure 3F](#fig3){ref-type="fig"}). Transwell assays indicated that IKK*α* knockdown markedly decreased OVCAR3 and SKOV3 cells\' invasion ([Figure 3G](#fig3){ref-type="fig"}). These results indicate that IKK*α* promotes the malignant phenotype of EOC cells, which is similar to the effects of miR-23a.

ST7L functions as a tumour suppressor in EOC cells
--------------------------------------------------

To determine the impact of ST7L on the phenotype of EOC cells, we constructed an ST7L overexpression vector (pcDNA3/ST7L) and a knockdown plasmid (shR-ST7L) ([Figure 4A and B](#fig4){ref-type="fig"}) and conducted functional assays. At 48 and 72 h posttransfection, OVCAR3 and SKOV3 cells viability were decreased by overexpression of ST7L and increased by ST7L knockdown ([Figure 4C](#fig4){ref-type="fig"}). In addition, relative colony-formation rate was increased by shR-ST7L and decreased by pcDNA3/ST7L compared with the control groups ([Figure 4D](#fig4){ref-type="fig"}). Furthermore, cell cycle analysis showed that ST7L overexpression increased the number of cells in G1 phase and decreased the number in S phase ([Figures 4E](#fig4){ref-type="fig"}, [Supplementary Figure S3B](#sup1){ref-type="supplementary-material"}), but ST7L was not observed to significantly influence cell apoptosis ([Supplementary Figure S4](#sup1){ref-type="supplementary-material"}). To determine whether ST7L influences the migration and invasion of EOC cells, migration (wound healing) and invasion (transwell) assays were performed in OVCAR3 and SKOV3 cells. As expected, overexpression of ST7L significantly suppressed OVCAR3 and SKOV3 cells\' migration and invasion, whereas shR-ST7L increased the migration and invasion of these cells ([Figure 4F and G](#fig4){ref-type="fig"}).

Because ST7L significantly decreased the migration and invasion of EOC cells, we tested whether ST7L affected the expression of key molecular markers of EMT, including E-cadherin, ICAM-1, and Vimentin. Western blotting analysis showed that overexpression of ST7L increased E-cadherin expression but decreased ICAM-1 and Vimentin expression in EOC cells. In contrast, miR-23a decreased E-cadherin protein levels but increased ICAM-1 and Vimentin protein levels in EOC cells ([Figure 4H](#fig4){ref-type="fig"}, [Supplementary Figure S5](#sup1){ref-type="supplementary-material"}). Taken together, these results indicate that ST7L suppresses malignant behaviour by repressing cell cycle and EMT.

Knockdown of IKK*α* and overexpression of ST7L partly rescue the tumorigenic phenotype induced by miR-23a in EOC cells
----------------------------------------------------------------------------------------------------------------------

To demonstrate that miR-23a may function as an oncogene by directly regulating IKK*α* and ST7L, we performed rescue versions of the proliferation, migration, and invasion experiments. As shown in [Figure 5A--D](#fig5){ref-type="fig"}, knockdown of IKK*α* partially rescued the phenotypes induced by miR-23a. Similarly, overexpression of ST7L partly rescued the malignant behaviour of EOC cells ([Figure 5E--H](#fig5){ref-type="fig"}).

miR-23a positively regulates the NF-*κ*B and WNT/MAPK pathways in EOC cells
---------------------------------------------------------------------------

Given that IKK*α* is essential for the NF-*κ*B pathway, we next investigated the possibility that miR-23a affects the activation of NF-*κ*B signaling pathway. The localization of NF-*κ*B in OVCAR3 cells was examined by immunofluorescence after transfection with pri-miR-23a or ASO-miR-23a and pcDNA3/IKK*α* or cotransfection with pri-miR-23a and shR-IKK*α*. The nuclear distribution of NF-*κ*B1 (p50) was increased in pri-miR-23a-transfected cells and decreased in ASO-miR-23a-transfected cells, which were treated with a low concentration of TNF-*α* ([Figure 6A](#fig6){ref-type="fig"}). Overexpression of IKK*α* increased the nuclear distribution of p50, and knockdown of IKK*α* partly rescued the effects of miR-23a ([Figure 6B](#fig6){ref-type="fig"}). We also demonstrated that the nuclear protein level of p50 was increased in cells transfected with pri-miR-23a and was decreased in cells transfected with shR-IKK*α*, and the cytoplasmic protein levels of p50 changed were shown, respectively ([Figure 6C and D](#fig6){ref-type="fig"}). To examine whether miR-23a influenced the activation of NF-*κ*B signaling pathway, we analyzed the expression level of the NF-*κ*B target gene IL-6 and CCL19 ([@bib20]) under alteration of miR-23a level in OVCAR3 and SKOV3 cell lines. RT--qPCR analysis showed that pri-miR-23a significantly increased the mRNA levels of IL-6 and CCL19 in OVCAR3 and SKOV3 cells ([Supplementary Figure S6](#sup1){ref-type="supplementary-material"}).

ST7L is an inhibitor of the WNT pathway ([@bib7]); to investigate the influence of miR-23a on the WNT signaling pathway, western blotting assays were utilised to detect downstream effectors of WNT signaling in cells transfected with miR-23a or ST7L. In both OVCAR3 and SKOV3 cells, the expression of wnt2, Dvl1, MAP3K7, and *β*-catenin, downstream effectors of the WNT/MAPK pathway, were reduced by miR-23a depletion and significantly increased by miR-23a restoration. Simultaneously overexpression of ST7L reversed the impact of miR-23a on wnt2, Dvl1, MAP3K7, and *β*-catenin expression ([Figure 6E and F](#fig6){ref-type="fig"}, [Supplementary Figure S5](#sup1){ref-type="supplementary-material"}). And TOP/FOP luciferase reporter assays were also performed, which is a common WNT pathway activation reporter assay ([@bib17]; [@bib24]); the results showed that miR-23a enhanced TOP/FOP flash ratio but ST7L weakened it ([Figure 6G](#fig6){ref-type="fig"}).

These results indicate that miR-23a modulates the NF-*κ*B and WNT pathways in a IKK*α*- and ST7L-dependent manner, respectively, in EOC cells.

Discussion
==========

miR-23a is organised in cluster with miR-27a and miR-24-2 and it has been reported that the three miRNAs derive from a single primary transcript. It was also reported that miR-23a and miR-27a are upregulated in serous OC and that they share common predicted targets belonging to WNT signaling pathway ([@bib10]). The miR-23a--miR-27a--miR-24-2 cluster may coordinately regulate several processes, and a previous report also demonstrated that miR-23a was upregulated in OC ([@bib35]). In the present study, we found that upregulation of miR-23a increased cell viability, growth, migration, and invasion by accelerating the G1/S transition and by inhibiting the apoptosis of OC cell lines. In addition, miR-23a activates NF-*κ*B pathway by upregulating IKK*α* and WNT/MAPK pathway by downregulating ST7L and promotes EMT process. These results indicate that miR-23a might function as an oncogene in OC.

ST7L functions as a tumour suppressor in many cancers ([@bib36]; [@bib7]). However, the role of ST7L in EOC cells was unknown. Our results demonstrated that ST7L suppressed cell proliferation, migration, and invasion, thus functioning as a tumour suppressor in EOC cells, and miR-23a downregulated ST7L expression to repress its function as tumour suppressor. These effects may be mediated by inhibiting the WNT/MAPK pathway to induce G1/S arrest and inhibit EMT process. WNT pathways are essential for development ([@bib6]) and have been implicated in tumorigenesis ([@bib39]).

Although it is well known that miRNAs target the 3′UTR of mRNAs and lead to mRNA decay or translation suppression, recent studies have revealed that miRNAs can result in posttranscriptional activation of target genes ([@bib40]). However, the detailed mechanism is poorly understood. In our study, the 3′UTR of IKK*α* was predicted to contain miR-23a-binding sites, and the EGFP report assay indicated that miR-23a targeted the 3′UTR and activated the reporter expression. IKK*α* has been reported to be upregulated in OC ([@bib5]); we also demonstrated that miR-23a significantly upregulated the expression of IKK*α*, and this upregulation by miR-23a was accompanied by an increase in classic NF-*κ*B signaling pathway activity in EOC cells, as evidenced by the elevated mRNA levels of IL-6 and CCL19, which are the reported targets of NF-*κ*B ([@bib14]; [@bib2]). Taken together, our results suggest that miR-23a may enhance NF-*κ*B activity by upregulating IKK*α* and demonstrate the increased level of IKK*α* upon miR-23a ectopic expression. As a result, we provide a new example of translation upregulation by miRNAs.

Collectively, our results reveal an oncogenic function of miR-23a in EOC cells. miR-23a upregulated the IKK*α* expression by binding the 3′UTR and thus increase the activity of the NF-*κ*B signaling pathway; miR-23a downregulated the ST7L expression by binding the 3′UTR and activated the WNT/MAPK pathway ([Figure 6H](#fig6){ref-type="fig"}). These findings may help us better understand the molecular mechanism of ovarian carcinogenesis and may have potentially diagnostic and therapeutic value in the future.
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![**miR-23a promotes the tumorigenic behaviour of EOC cells.** (**A**) Relative level of miR-23a after transfection with pri-miR-23a or ASO-miR-23a. (**B**) Cell viability was determined at 48 h and 72 h posttransfection by MTT assays after transfection with pri-miR-23a or ASO-miR-23a. (**C**) *In vitro* cell growth was also assessed by colony-formation assays; relative colony-formation rate are shown. (**D**) Cell cycle assays showed that miR-23a increased the number of OVCAR3 cells in S phase. (**E**) miR-23a suppressed the apoptosis of OVCAR3 cells. (**F**) Wound-healing assays were used to measure migration at 0, 48, and 72 h; and the quantitative pattern are shown. (**G**) Transwell assays showed the invasion tendency. All of the experiments were repeated three times. \**P*\<0.05; \*\**P*\<0.01; \*\*\**P*\<0.001.](bjc2016244f1){#fig1}

![**miR-23a upregulates IKK*α* expression but suppresses ST7L expression by targeting their 3′UTRs in EOC cells.** (**A**) The predicted miR-23a-binding sites in IKK*α* (labelled as CHUK) and ST7L mRNA using Targetscan 7.0 are shown. (**B**) OVCAR3 and SKOV3 cells were cotransfected with wild-type pcDNA3/EGFP-IKK*α* 3′UTR or (**C**) 3′UTR-mut and pri-miR-23a or ASO-miR-23a. (**D**) OVCAR3 and SKOV3 cells were cotransfected with pcDNA3/EGFP-ST7L 3′UTR or (**E**) 3′UTR-mut and pri-miR-23a or ASO-miR-23a. (**F** and **G**) Reverse transcription--quantitative PCR and western blotting showed IKK*α* and ST7L mRNA and protein levels after transfection with pri-miR-23a or ASO-miR-23a. All of the experiments were repeated three times. \*\**P*\<0.01; \*\*\**P*\<0.001; NS, not significant.](bjc2016244f2){#fig2}

![**Knockdown of IKK*α* inhibits EOC cell growth, migration, and invasion.** (**A** and **B**) Reverse transcription--quantitative PCR and western blotting showed that knockdown of IKK*α* is efficient. (**C**) MTT assays showed that transfection with shR-IKK*α* suppresses cellular viability. (**D**) Colony-formation rate in OVCAR3 and SKOV3 cells transfected with shR-IKK*α* were lower compared with the control groups. (**E**) Knockdown of IKK*α* promoted the apoptosis of OVCAR3 cells. (**F**) Wound-healing assays showed that knockdown of IKK*α* suppresses OVCAR3 and SKOV3 cells\' migration at 0, 48, and 72 h. (**G**) Transwell assays showed that knockdown of IKK*α* suppresses cells\' invasion. All of the experiments were repeated three times. \*\**P*\<0.01; \*\*\**P*\<0.001.](bjc2016244f3){#fig3}

![**ST7L functions as a tumour suppressor.** (**A** and **B**) Reverse transcription--quantitative PCR and western blotting showed that overexpression and knockdown of ST7L are efficient. (**C**) MTT assays showed that overexpression of ST7L inhibited cell viability and knockdown of ST7L increased cell viability. (**D**) Colony-formation rate were lower after transfection with pcDNA3/ST7L and higher after transfection with shR-ST7L compared with the control groups. (**E**) The cell cycle profiles after treatment with pcDNA3/ST7L or shR-ST7L were detected by flow cytometry. (**F**) Wound-healing assays showed that migration was suppressed by overexpression of ST7L and promoted by knockdown of ST7L. (**G**) Transwell assays showed that overexpression of ST7L inhibited invasion. (**H**) Western blotting showed the protein levels of ICAM-1, Vimentin, and E-cadherin after transfection with pri-miR-23a or ASO-miR-23a and pcDNA3/ST7L or shR-ST7L. All of the experiments were repeated three times. \**P*\<0.05; \*\**P*\<0.01; \*\*\**P*\<0.001.](bjc2016244f4){#fig4}

![**Knockdown of IKK*α* and overexpression of ST7L partly rescue the tumour phenotype induced by miR-23a.** Cotransfection with pri-miR-23a and shR-IKK*α* showed that IKK*α* knockdown partly rescued cell (**A** and **B**) proliferation, (**C**) migration, and (**D**) invasion. Cotransfection with pri-miR-23a and pcDNA3/ST7L showed that overexpression of ST7L partly rescued cell (**E** and **F**) proliferation, (**G**) migration, and (**H**) invasion. All of the experiments were repeated three times. \**P*\<0.05; \*\**P*\<0.01; \*\*\**P*\<0.001; NS, not significant.](bjc2016244f5){#fig5}

![**miR-23a positively regulates the NF-*κ*B and WNT/MAPK pathways.** (**A**--**D**) OVCAR3 cells were transfected with the indicated combinations of pri-miR-23a, ASO-miR-23a, pcDNA3/IKK*α*, pri-miR-23a, and shR-IKK*α*. After 48 h, cells were harvested, and p50 was detected by immunofluorescent staining and western blotting. n-p50: nuclear p50, the control group was CENPA; c-p50: cytoplasmic p50, the control group was GAPDH (glyceraldehyde 3-phosphate dehydrogenase). (**E**) Western blotting were used to measure the protein levels after transfection with pri-miR-23a or ASO-miR-23a. (**F**) Western blotting showed the protein levels in cells treated with pcDNA3/ST7L or shR-ST7L. (**G**) OVCAR3 and SKOV3 cells were cotransfected with pTOP/flash or pFOP/flash, pcDNA3, pri-miR-23a, pcDNA3/ST7L, or pri-miR-23a and pcDNA3/ST7L, respectively, after which luciferase reporter assays were performed. (**H**) The model by which miR-23a upregulates IKK*α* and downregulates ST7L to activate NF-*κ*B and WNT/MAPK pathways to promote tumour malignancy. All of the experiments were repeated three times. \**P*\<0.05; \*\**P*\<0.01; \*\*\**P*\<0.001; NS, not significant.](bjc2016244f6){#fig6}
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